The ABCC5 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting ABCC5 in the human SK-HEP-1 liver adenocarcinoma cell line. This product provides a heterogeneous mixture of cells with disrupted ABCC5 alleles via CRISPR/Cas9-mediated gene disruption, enabling loss-of-function studies of the multidrug resistance protein MRP5 without single-cell cloning.
SK-HEP-1 cells are a widely used human liver adenocarcinoma cell line derived from ascitic fluid, exhibiting both epithelial and endothelial characteristics. This unique phenotype makes them a relevant model for hepatocellular carcinoma research, particularly for studying drug transport and chemoresistance mechanisms in liver cancer.
ABCC5 encodes the ATP-dependent transporter MRP5, which actively effluxes organic anions, notably the cyclic nucleotides cAMP and cGMP, as well as conjugated metabolites of anticancer drugs, across the plasma membrane. MRP5 is transcriptionally regulated by Nrf2 and modulated by Wnt signaling and microRNAs including miR-205 and miR-367. The transporter interacts with substrate molecules and may associate with other ABC transporter family members and cytosolic adaptor proteins. By controlling the intracellular concentrations of cAMP and cGMP, MRP5 governs the activation of PKA and PKG and impacts phosphodiesterase activity. CRISPR/Cas9-mediated disruption of ABCC5 abolishes this efflux function, resulting in cyclic nucleotide accumulation and potential chemosensitization.
In hepatocellular carcinoma, MRP5-mediated efflux of chemotherapeutic agents is a critical determinant of multidrug resistance, as MRP5 can transport drugs such as 5-fluorouracil and cisplatin. Knockout of ABCC5 in SK-HEP-1 cells impairs the removal of these anticancer compounds, leading to elevated intracellular drug retention and increased cytotoxicity. This model is also regulated by pathways such as Nrf2 and Wnt, enabling interrogation of how these signals intersect with transporter activity. Furthermore, the consequent accumulation of cyclic nucleotides provides a unique system to study how cAMP/PKA and cGMP/PKG signaling dynamics influence liver cancer cell proliferation and survival.
These polyclonal knockout cells support a diverse range of research applications, including mechanistic studies of multidrug resistance in hepatocellular carcinoma, examination of cyclic nucleotide signaling crosstalk, and high-throughput screening for MRP5 substrates or inhibitors. Validation can be performed via RT-qPCR and Western blot for MRP5, while functional assays such as calcein-AM efflux, intracellular cAMP/cGMP ELISA, and cell viability assays with chemotherapeutics enable detailed phenotypic characterization. For additional information, technical support, or custom project inquiries, please contact Ascent Research.
